Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biodexa Pharmaceuticals plc - American Depositary Shares
(NQ:
BDRX
)
6.330
+0.220 (+3.60%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Oct 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biodexa Pharmaceuticals plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
May 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 21, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
May 21, 2024
Pre-market stock movers are worth checking out as we have all of the hottest market news available on Tuesday morning!
Via
InvestorPlace
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
May 09, 2024
Via
ACCESSWIRE
Why Is Biodexa (BDRX) Up 70% Today?
April 26, 2024
Oncology specialist Biodexa inked a compelling licensing deal to treat a serious disease, and BDRX stock popped sharply higher.
Via
InvestorPlace
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
March 28, 2024
Via
ACCESSWIRE
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
March 01, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 29, 2024
Via
Benzinga
Why Is Inno (INHD) Stock Up 46% Today?
April 29, 2024
Inno stock is rising higher on Monday as INHD shares experience heavy trading this morning despite a lack of news from the company.
Via
InvestorPlace
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
April 29, 2024
Via
Benzinga
Dow Surges Over 200 Points; Microsoft Shares Gain Following Upbeat Earnings
April 26, 2024
Via
Benzinga
Topics
Stocks
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 26, 2024
Via
Benzinga
S&P 500 Gains 1%; Exxon Mobil Posts Downbeat Earnings
April 26, 2024
Via
Benzinga
Topics
Stocks
US Stocks Higher Following PCE Inflation Data; Nasdaq Jumps Over 200 Points
April 26, 2024
Via
Benzinga
Topics
Economy
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
March 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 28, 2024
Via
Benzinga
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
March 28, 2024
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 15 points on Thursday. The Dow traded up 0.06% to 39,785.29 while the NASDAQ fell 0.13% to 16,383.85. The...
Via
Benzinga
Topics
Stocks
Extend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential
March 28, 2024
Biodexa Pharmaceuticals' MTX110, revolutionizing brain cancer treatment with innovative drug delivery technology. Early trials show promising survival rate extensions in Diffuse Midline Glioma and...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 28, 2024
Via
Benzinga
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 28, 2024
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of...
Via
Benzinga
Gold Gains 1%; Walgreens Narrows Earnings Forecast
March 28, 2024
U.S. stocks traded slightly higher midway through trading, with the S&P 500 gaining around 0.1% on Thursday. The Dow traded up 0.06% to 39,785.87 while the NASDAQ rose 0.06% to 16,408.04. The S&P 500...
Via
Benzinga
Topics
Stocks
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?
March 28, 2024
Biodexa Pharmaceuticals stock is up alongside heavy trading of BDRX after announcing positive news from a brain cancer treatment trial.
Via
InvestorPlace
US Stocks Flat; Initial Jobless Claims Fall To 210,000
March 28, 2024
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
March 18, 2024
Via
Benzinga
What's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday?
February 23, 2024
Biodexa Pharmaceuticals shares R&D update, revealing Phase 1 trial results for MTX110 in diffuse midline glioma patients. Study shows promising median overall survival of 16.5 months.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 14, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.